QCG
ITCI

Quadrant Capital Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Quadrant Capital Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-139
Closed -$18.3K – 2741
2025
Q1 		$18.3K Buy
139
+90
+184% +$11.2K ﹤0.01% 2061
2024
Q4 		$4.09K Hold
49
– – ﹤0.01% 2351
2024
Q3 		$3.59K Hold
49
– – ﹤0.01% 2387
2024
Q2 		$3.36K Buy
49
+4
+9% +$277 ﹤0.01% 2383
2024
Q1 		$3.11K Hold
45
– – ﹤0.01% 2416
2023
Q4 		$3.22K Buy
45
+33
+275% +$1.9K ﹤0.01% 2375
2023
Q3 		$626 Sell
12
-4
-25% -$233 ﹤0.01% 2539
2023
Q2 		$1.01K Hold
16
– – ﹤0.01% 2497
2023
Q1 		$867 Buy
16
+7
+78% +$338 ﹤0.01% 2554
2022
Q4 		$476 Sell
9
-73
-89% -$3.66K ﹤0.01% 2628
2022
Q3 		$4K Sell
82
-30
-27% -$1.57K ﹤0.01% 2244
2022
Q2 		$6K Buy
112
+103
+1,144% +$5.84K ﹤0.01% 1924
2022
Q1 		$1K Hold
9
– – ﹤0.01% 2428
2021
Q4 		$0 Buy
9
+5
+125% +$210 ﹤0.01% 2729
2021
Q3 		$0 Hold
4
– – ﹤0.01% 2688
2021
Q2 		$0 Sell
4
-15
-79% -$554 ﹤0.01% 2604
2021
Q1 		$1K Buy
+19
New +$659 ﹤0.01% 2325
2020
Q4 		– Sell
-8
Closed – – 2393
2020
Q3 		$0 Sell
8
-13
-62% -$297 ﹤0.01% 2339
2020
Q2 		$1K Buy
+21
New +$425 ﹤0.01% 2167

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Quadrant Capital Group's ITCI Position: Q2 2025 in Review

Quadrant Capital Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 139 shares — an estimated $18.3K sold.

Quadrant Capital Group first reported a position in ITCI in Q2 2020 and held it in 19 quarters. The position peaked at $18.3K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Quadrant Capital Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 139 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $18.3K.
  • Quadrant Capital Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 19 quarters.
  • Quadrant Capital Group's Intra-Cellular Therapies Inc. position peaked at $18.3K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Quadrant Capital Group's 13F filing for Q2 2025, filed 13 Aug 2025.